News headlines about Synergy Pharmaceuticals (NASDAQ:SGYP) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.3041627318093 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- With FDA Approvals in Sight, Will Synergy Pharmaceuticals and Agile Therapeutics Skyrocket as H.C Wainwright Predicts? (finance.yahoo.com)
- Hair-Raising Facts to Know – Synergy Pharmaceuticals Inc., (NASDAQ: SGYP) – Stock Watch (stocksnewstimes.com)
- Notable Intraday Movers – Synergy Pharmaceuticals Inc., (NASDAQ: SGYP), Eli Lilly and Company, (NYSE: LLY) – Stocks In The News (press release) (tradingnewsnow.com)
- Synergy Pharmaceuticals Inc. (SGYP) Needs Strong Boost to Get Active Moment in Street – Stock News Stop (stockmarketstop.com)
- Take These As A Wake-Up Bell: Synergy Pharmaceuticals Inc. (SGYP), Netflix, Inc. (NFLX) – Market Movers (financialqz.com)
Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) traded down $0.05 during mid-day trading on Friday, reaching $1.84. The company had a trading volume of 5,151,500 shares, compared to its average volume of 5,925,194. Synergy Pharmaceuticals has a 52-week low of $1.68 and a 52-week high of $7.15. The company has a current ratio of 4.26, a quick ratio of 3.88 and a debt-to-equity ratio of -68.13.
A number of research analysts have recently issued reports on the company. Rodman & Renshaw dropped their target price on Synergy Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, August 10th. Oppenheimer dropped their target price on Synergy Pharmaceuticals from $9.00 to $6.00 and set an “outperform” rating on the stock in a report on Friday, September 8th. Cantor Fitzgerald reissued a “buy” rating and issued a $10.00 target price on shares of Synergy Pharmaceuticals in a report on Tuesday, November 21st. HC Wainwright set a $15.00 target price on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 10th. Finally, CIBC dropped their target price on Synergy Pharmaceuticals from $9.00 to $6.00 and set an “outperform” rating on the stock in a report on Friday, September 8th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Synergy Pharmaceuticals has an average rating of “Hold” and an average price target of $7.84.
In related news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $2.82, for a total transaction of $24,675,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 3.80% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Synergy Pharmaceuticals (SGYP) Share Price” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/12/08/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-synergy-pharmaceuticals-sgyp-share-price.html.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
What are top analysts saying about Synergy Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Synergy Pharmaceuticals Inc. and related companies.